Cellular Biomedicine Group Reports Second Quarter and First Half 2015 Financial Results and Business Highlights
|
|
- Kerry Lucas
- 6 years ago
- Views:
Transcription
1 Cellular Biomedicine Group Reports Second Quarter and First Half 2015 Financial Results and Business Highlights SHANGHAI, China and PALO ALTO, Calif., August 14, 2015 /GlobeNewswire/ - - Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ( CBMG or the Company ), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today reported financial results and business highlights for the quarter and six months ended June 30, "I am pleased with our second quarter progress in reaching certain planned milestones and in strengthening both our business and technological advantages, said Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group. In addition to our international- standard Shanghai GMP facility passing its 4th consecutive China Food and Drug Administration (CFDA) inspection, we are expanding our GMP coverage with another 15,000 square feet site in Beijing, our third GMP facility. We are also delighted to have industry veterans Richard Wang Ph.D. join us as Chief Operating Officer, and Yihong Yao, Ph.D., join us as Chief Scientific Officer. I m proud of our team achieving several accolades comprised of publication on the use of human adipose- derived progenitor cells (hampcs) demonstrating efficacy in a rabbit OA model for treating knee osteoarthritis (KOA) in a peer- reviewed scientific journal, and dissemination of positive Phase I clinical data on the Chimeric Antigen Receptor T- cell (CAR- T) immuno- oncology clinical development programs: CD19 for Acute Lymphocytic Leukemia (B- cell ALL); and CD20 for Advanced Diffuse Large B Cell Lymphoma (DLBCL), and; CD30 for Hodgkin s lymphoma. We have confirmed that the trials are safe and remain optimistic about their potential disease efficacy. Furthermore, we added the CD40LGVAX cancer vaccine targeting Non Small Cell Lung Cancer (NSCLC) to our portfolio. We believe the Company is well positioned as a leader in degenerative and cancerous therapies to serve the large patient population, concluded Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group. In addition to CBMG s NASDAQ upgrade to the higher tiered Global Markets, I am pleased that we are now part of the broad- market Russell 3000 Index which will increase visibility with institutional investors across key financial markets, commented Tony (Bizuo) Liu, Chief Financial Officer of the Company. We believe that health care is a universally defensive sector and CBMG is now equipped to deliver on our clinical milestones and to build a world- class biotechnology firm focused on providing solutions that address large unmet global medical needs. Second Quarter and First Half 2015 Financial Performance 1. Cash Position: Cash and cash equivalents as of June 30, 2015 were $23.7 million compared to $14.8 million as of December 31, Our cash position increased as we had an increase in cash generated from financing activities due to a private placement financing in March 2015 for aggregate gross proceeds of approximately $19,600,000 through the sale of 515,786 shares of Common Stock, partially offset by an increase in cash used in operating activities.
2 2. Net Cash Used in Operating Activities: Net cash used in operating activities for the quarter and six months ended June 30, 2015 was $3.3 million and $5.7 million, respectively, compared to $2.3 million and $4.7 million for the same periods in Revenue: Revenues for the quarter and six months ended June 30, 2015 were $0.7 million and $1.3 million, respectively, compared to $0.1 million and $0.2 million for the same periods in In late 2014, with the acquisition of AG, we started generating revenue from technology services. All the revenue was derived from technology services for the three months ended June 30, 2015, while revenue was solely from sales of A- Stromal TM kits during the same period in G&A Expenses: General and administrative expenses for the quarter and six months ended June 30, 2015 were $3.8 million and $6.4 million, respectively, compared to $1.6 million and $3 million for the same periods in Increased expenses in the three months ended June 30, 2015 was associated with increased corporate activities related to the management and the development of our biomedicine business and was primarily attributed to the below facts: An increase in stock- based compensation expense of $1,172,000, which primarily resulted from the new grants and higher fair value of unvested options after the Company listed on Nasdaq in June 2014 compared with those unvested options as of June 30, 2014; An increase in depreciation and amortization of $180,000, which was mainly attributed to the technology and patents obtained from the acquisition of AG in third quarter 2014; An increase in rental expenses of $144,000, which was mainly attributed to the new lease agreement concluded for the construction of the Beijing GMP; and An increase in legal, accounting and other professional services of $465, R&D Expenses: Research and development expenses for the quarter and six months ended June 30, 2015 were $1.3 million and $2.8 million respectively, compared to $0.7 million and $1.3 million for the same periods in Research and development costs increased by approximately $603,000 in the three months ended June 30, 2015 as compared to the three months ended June 30, 2014 due primarily to an increase of our immunotherapy research and development team, which resulted in an increase in payroll expenses of $217,000; an increase in stock- based compensation expenses of $284,000 and an increase in rental of $34, Net Loss: Net loss allocable to common stock holders for the quarter and six months ended June 30, 2015 was $5 million and $9.3 million respectively, compared to $6.7 million and $7.1 million for the same periods in Changes in net loss are primarily attributable to changes in operations of our biomedicine segment and the discontinued consulting segment. During and since the second quarter of 2015, Cellular Biomedicine Group strengthened its position as a leading pure- play biotechnology company by achieving the following milestones and significant events: Business Highlights Appointment of Richard L. Wang, Ph.D., MBA, PMP as Chief Operating Officer Appointment of Yihong Yao, Ph.D., B.S. as Chief Scientific Officer Appointment of Alan List, M.D. as Chair of the Scientific Advisory Board Acquisition of Blackbird Bio Finance and University of South Florida s next generation GVAX vaccine s (CD40LGVAX) related technologies and technical knowledge Selected to be included in the broad- market Russell 3000 Index Publication of the use of human adipose- derived progenitor cells (hampcs) demonstrating efficacy in a rabbit OA model for treating knee osteoarthritis (KOA) in peer- reviewed scientific journal International Journal of Molecular Sciences Technology Achievements Received two new certifications from the China Food and Drug Administration (CFDA) for each of its proprietary cell and tissue preservation media kits Announced positive Phase I Results From CAR- T CD30 Immuno- Oncology Clinical Development Program, demonstrating the trial to be safe, feasible and efficacious
3 Upcoming Events In the next twelve months the Company aims to accomplish the following significant milestones: Complete the preclinical GLP safety evaluation studies of hampc for Asthma and Chronic Obstructive Pulmonary Disease Evaluate the feasibility of sponsoring a Phase I/II clinical study to support the New Drug Application (NDA) for the U.S. CD40LGVAX trial Publish Phase I clinical trial results for CAR- T EGFR- HER1- positive for advanced lung cancer Publish ReJoin TM KOA Phase IIb twelve- month data Obtain approval for pending Patent Cooperation Treaty ( PCT ) patents Develop a strategy to prioritize and launch cancer immune cell therapy clinical trials Launch Phase II trials to explore the efficacy and safety of CD19 or CD20 CAR- T mono or combination therapies in chemo refractory/relapsing patients with hematological malignancies Prepare preclinical package to apply for clinical trial of allogeneic hampc therapy for COPD/Asthma About Cellular Biomedicine Group Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative and cancerous diseases. Our developmental stem cell and Immuno- Oncology projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of six independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: Forward- Looking Statements Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward- looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG s reports filed with the Securities and Exchange Commission, quarterly reports on form 10- Q, current reports on form 8- K and annual reports on form 10- K. Forward- looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward- looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward- looking statements other than as required by law.
4 CELLULAR BIOMEDICINE GROUP, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) June 30, December 31, Assets Cash and cash equivalents $23,651,084 $14,770,584 Accounts receivable 445, ,029 Other receivables 453, ,957 Inventory 400, ,249 Prepaid expenses 551, ,299 Other current assets - 110,347 Total current assets 25,501,440 16,095,465 Investments 14,819,407 6,886,033 Property, plant and equipment, net 1,322,099 1,280,410 Goodwill 7,678,789 7,678,789 Intangibles, net 16,817,661 11,156,676 Long-term prepaid expenses and other assets 915, ,729 Total assets $67,054,852 $43,685,102 Liabilities and Stockholders' Equity Liabilities: Accounts payable $106,612 $426,917 Accrued expenses 2,927,200 2,074,384 Taxes payable 640, ,288 Advances payable to related party - 36,254 Other current liabilities 1,543, ,479 Total current liabilities 5,217,951 4,076,322 Other non-current liabilities 240, ,689 Total liabilities 5,458,399 4,529,011 Stockholders' equity: Preferred stock, par value $.001, 50,000,000 shares authorized; none issued and outstanding as of June 30, 2015 and December 31, 2014, respectively - - Common stock, par value $.001, 300,000,000 shares authorized; 11,610,665 and 10,990,335 issued and outstanding as of June 30, 2015 and December 31, 2014, respectively 11,611 10,990 Additional paid in capital 99,095,398 75,467,316 Accumulated deficit (47,204,236) (37,890,590) Accumulated other comprehensive income (loss) 9,693,680 1,568,375 Total stockholders' equity 61,596,453 39,156,091 Total liabilities and stockholders' equity $67,054,852 $43,685,102
5 CELLULAR BIOMEDICINE GROUP, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) For the Six Months Ended June 30, CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $(9,313,646) $(7,120,794) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 928, ,015 Loss on disposal of assets - 10,358 Stock based compensation expense 3,618, ,622 Amortisation of deferred stock compensation - 63,518 Other than temporary impairment on investments 123,428 - Realized losses from sale of investments 5,178 5,913 Value of stock received for services - (1,610,000) Impairment of goodwill - 3,299,566 Changes in operating assets and liabilities: Accounts receivable (304,173) (13,419) Other receivables (222,716) 15,452 Inventory (27,839) (37,371) Prepaid expenses (8,427) (245,901) Other current assets 110,347 - Investments - 7,150 Long-term prepaid expenses and other assets (73,031) (498,888) Accounts payable (320,305) (104,794) Accrued expenses 112, ,889 Advance payable to related party (30,216) - Other current liabilities 88,991 (110,980) Taxes payable (173,739) - Other non-current liabilities (212,265) - Net cash used in operating activities (5,699,806) (4,722,664) CASH FLOWS FROM INVESTING ACTIVITIES: Proceed from sale of investments, net of transaction costs 1,480 - Purchases of intangible assets (4,385,940) - Purchases of property, plant and equipment (224,826) (77,537) Net cash used in investing activities (4,609,286) (77,537) CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from the issuance of common stock 18,964,849 11,221,956 Proceeds from exercise of stock options 234,599 - Repayment of advance from affiliate - (33,528) Net cash provided by financing activities 19,199,448 11,188,428 EFFECT OF EXCHANGE RATE CHANGES ON CASH (9,856) 79 INCREASE IN CASH AND CASH EQUIVALENTS 8,880,500 6,388,306 CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 14,770,584 7,175,215 CASH AND CASH EQUIVALENTS, END OF PERIOD $23,651,084 $13,563,521 SUPPLEMENTAL CASH FLOW INFORMATION Cash paid for income taxes $(226,855) $- Non-cash investing activities Acquisition of intangible assets through issuance of the Company's stock $1,096,399 $-
6 CELLULAR BIOMEDICINE GROUP, INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) For the Three Months Ended For the Six Months Ended June 30, June 30, Net sales and revenue $656,959 $118,069 $1,260,349 $179,120 Operating expenses: Cost of sales 398,229 51, ,291 92,553 General and administrative 3,768,535 1,642,758 6,448,772 2,954,761 Selling and marketing 161,219 44, ,241 65,495 Research and development 1,322, ,388 2,778,112 1,288,044 Impairment of investments ,428 - Total operating expenses 5,650,675 2,458,235 10,552,844 4,400,853 Operating loss (4,993,716) (2,340,166) (9,292,495) (4,221,733) Other income (expense): Interest income 5, , Other income (expense) 13,523 74,480 10,820 94,617 Total other income 19,443 74,821 31,851 95,182 Loss from continuing operations before taxes (4,974,273) (2,265,345) (9,260,644) (4,126,551) Income taxes provision (52,202) - (53,002) - Loss from continuing operations (5,026,475) (2,265,345) (9,313,646) (4,126,551) Loss on discontinued operations, net of taxes - (4,408,918) - (2,994,243) Net loss $(5,026,475) $(6,674,263) $(9,313,646) $(7,120,794) Other comprehensive income (loss): Cumulative translation adjustment 42,236 4,978 61,845 (6,835) Unrecognized gain (loss) on investments 10,631,731 4,042,797 8,063,460 3,521,349 Total other comprehensive loss: 10,673,967 4,047,775 8,125,305 3,514,514 Comprehensive income (loss) $5,647,492 $(2,626,488) $(1,188,341) $(3,606,280) Loss per share for continuing operations: Basic $(0.44) $(0.29) $(0.83) $(0.54) Diluted $(0.44) $(0.29) $(0.83) $(0.54) Loss per share for discontinued operations: Basic $- $(0.56) $- $(0.39) Diluted $- $(0.56) $- $(0.39) Net loss per share : Basic $(0.44) $(0.85) $(0.83) $(0.93) Diluted $(0.44) $(0.85) $(0.83) $(0.93) Weighted average common shares outstanding: Basic 11,531,497 7,829,314 11,286,712 7,660,974 Diluted 11,531,497 7,829,314 11,286,712 7,660,974
7
Cellular Biomedicine Group, Inc.
SECURITIES & EXCHANGE COMMISSION EDGAR FILING Cellular Biomedicine Group, Inc. Form: 10-K Date Filed: 2017-03-13 Corporate Issuer CIK: 1378624 Copyright 2017, Issuer Direct Corporation. All Right Reserved.
More informationKite Pharma Reports First Quarter 2015 Financial Results
May 15, 2015 Kite Pharma Reports First Quarter 2015 Financial Results SANTA MONICA, Calif., May 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company
More informationFortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY November 9, 2016 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More informationFortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY November 9, 2018 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More informationAffimed Reports Financial Results for Second Quarter 2018 and Operational Progress
FOR IMMEDIATE RELEASE Affimed Reports Financial Results for Second Quarter 2018 and Operational Progress Heidelberg, Germany, August 8, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical
More informationAffimed Reports Financial Results for First Quarter 2018
FINAL FOR IMMEDIATE RELEASE Affimed Reports Financial Results for First Quarter 2018 Heidelberg, Germany, May 15, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused
More informationReceived FDA approval to expand the ATHENA trial of Cytori s cell therapy for chronic ischemic heart failure
August 8, 2013 Cytori Reports First Half and 2 nd Quarter 2013 Business and Financial Results San Diego, CA - Cytori Therapeutics (NASDAQ: CYTX) today reports its second quarter 2013 financial results
More informationABB Ltd Interim Consolidated Income Statements (unaudited) Six months ended
ABB Ltd Interim Consolidated Income Statements (unaudited) ($ in millions, except per share data in $) Jun. 30, 2012 Jun. 30, 2011 Jun. 30, 2012 Jun. 30, 2011 Sales of products 15'501 15'207 8'078 8'154
More informationABB Ltd Interim Consolidated Income Statements (unaudited)
ABB Ltd Interim Consolidated Income Statements (unaudited) ($ in millions, except per share data in $) Dec. 31, 2014 Dec. 31, 2013 Dec. 31, 2014 Dec. 31, 2013 Sales of products 33,279 35,282 8,545 9,549
More informationGILAT SATELLITE NETWORKS LTD. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS U.S. dollars in thousands (except share and per share data)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (except share and per share data) 2016 2015 2016 2015 Audited Revenues $ 279,551 $ 197,543 $ 80,345 $ 67,682 Cost of revenues 204,061 143,318 56,147 47,181
More informationAffimed Reports Financial Results for Third Quarter 2018 and Operational Progress
FOR IMMEDIATE RELEASE Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress - Established strategic collaboration agreement with Genentech for NK cell engager-based immunotherapeutics:
More informationABB Ltd Interim Consolidated Income Statements (unaudited)
ABB Ltd Interim Consolidated Income Statements (unaudited) ($ in millions, except per share data in $) Sep. 30, 2014 Sep. 30, 2013 Sep. 30, 2014 Sep. 30, 2013 Sales of products 24,734 25,733 8,255 8,948
More informationFull Year and Fourth Quarter Highlights
Osiris Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results: For the Full Year, Revenue Increased 146% and Company Reports Record Revenue in Fourth Quarter. COLUMBIA, Md. March 5, 2015
More informationFortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY May 10, 2018 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company dedicated
More informationKITE PHARMA, INC. FORM 10-Q. (Quarterly Report) Filed 05/08/17 for the Period Ending 03/31/17
KITE PHARMA, INC. FORM 10-Q (Quarterly Report) Filed 05/08/17 for the Period Ending 03/31/17 Address 2225 COLORADO AVENUE SANTA MONICA, CA 90404 Telephone (310) 824-9999 CIK 0001510580 Symbol KITE SIC
More informationABB Ltd Interim Consolidated Income Statements (unaudited) Year ended
ABB Ltd Interim Consolidated Income Statements (unaudited) ($ in millions, except per share data in $) Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2013 Dec. 31, 2012 Sales of products 35,282 32,979 9,549 9,251
More informationCytori Reports First Quarter 2014 Business and Financial Results
CYTORI THERAPEUTICS CONTACT Megan McCormick +1.858.875.5279 mmccormick@cytori.com Cytori Reports First Quarter 2014 Business and Financial Results San Diego, CA, May 12, 2014 Cytori Therapeutics (NASDAQ:
More informationHeat Biologics, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly
More informationSelling, general and administrative expenses 35,645 33,787. Net other operating income (292) (270) Operating profit 44,202 17,756
Condensed Interim Consolidated Income Statement For the quarter ended September 30 Continuing operations Revenue 328,071 258,941 Cost of sales 248,516 207,668 Gross profit 79,555 51,273 Selling, general
More informationDigital River, Inc. Second Quarter Results (Unaudited, in thousands) Subject to reclassification
(Unaudited, in thousands) Condensed Consolidated Balance Sheets As of December 31, 2008 2007 Assets: Current assets Cash and cash equivalents $ 276,927 $ 381,788 Short-term investments 201,297 315,636
More informationXOMA Reports First Quarter 2006 Results *********************************************************************
News Release Paul Goodson Investor Relations Tel: (510) 204-7270 XOMA Reports First Quarter 2006 Results ********************************************************************* Berkeley, CA May 10, 2006
More informationAstex Pharmaceuticals Reports 2013 Second Quarter Financial Results
News Release Astex Pharmaceuticals Reports 2013 Second Quarter Financial Results SGI-110 clinical data presented at EHA for Phase 1 MDS patients Second quarter royalty revenue increased 15% to $16.6 million
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) December 31, 2015 December 31, 2014 December 31, 2015 December 31, 2014 Revenues: Subscription $ 244,702
More informationNektar Therapeutics Reports Financial Results for the Third Quarter of 2017
November 7, 2017 Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017 SAN FRANCISCO, Nov. 7, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial
More informationJuno Therapeutics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationCellectis S.A. (Exact Name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report:
More informationO: O:
For investors For media Agnes Lee Alison Graves O: 858-836-5971 O: 858-836-6789 investorrelations@resmed.com news@resmed.com ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2018 Revenue
More informationThree Months Ended Twelve Months Ended 12/31/ /31/ /31/ /31/
Consolidated Statements of Operations (In thousands, except share and per share data) TABLE 1 Software licenses $11,336 $8,901 $37,859 $30,709 Support and maintenance 12,631 12,194 49,163 45,591 Professional
More informationDigital River, Inc. First Quarter Results (In thousands, except share data) Subject to reclassification
(In thousands, except share data) Consolidated Balance Sheets (Unaudited) December 31, Assets Current assets Cash and cash equivalents $ 500,742 $ 542,851 Short-term investments 144,615 162,794 Accounts
More informationPieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 10, 2018 Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MAY 10, 2018 AT 8:00 AM EDT BOSTON,
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) Revenues: Subscription $ 166,751 $ 104,878 $ 567,217 $ 349,804 Professional services and other 31,253 20,352
More informationResMed Inc. Announces Results for the First Quarter of Fiscal Year Revenue increased 8% to $412 million; up 15% on a constant currency basis
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2016 Revenue increased 8% to $412 million; up 15% on a constant currency basis GAAP diluted earnings per share of $0.57, or non-gaap earnings
More informationCYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Earliest Event Reported)
More informationKadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results -- Multiple Clinical Data Readouts Expected Throughout 2017 -- NEW YORK, March 22, 2017 Kadmon Holdings, Inc.
More informationPLURISTEM THERAPEUTICS INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 o TRANSITION REPORT UNDER
More informationAcorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016
NEWS RELEASE Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 2/14/2017 AMPYRA (dalfampridine) 4Q 2016 Net Revenue of $132 Million; Full-Year Net Revenue of $493 Million
More information2008 Fourth Quarter Financial Results Year-Over-Year:
Celgene Reports Record Fourth Quarter and Full Year 2008 Product Sales and Operating Profits SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG): REVLIMID #1 Therapy in Multiple Myeloma
More informationOsiris Therapeutics Announces Third Quarter 2015 Financial Results
Osiris Therapeutics Announces Third Quarter 2015 Financial Results COLUMBIA, Md. November 6, 2015 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused
More informationResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2018
For investors For media Amy Wakeham Jayme Rubenstein O: 858-836-5000 O: 858-836-6798 investorrelations@resmed.com news@resmed.com ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2018
More informationYasheng Group 2010 Financial Results
Yasheng Group 2010 Financial Results CONSOLIDATED BALANCE SHEETS 2010 2009 2008 ASSETS 849,454,265 739,630,043 736,213,299 Current assets: Cash and cash equivalents 10,116,750 8,010,017 7,880,338 Accounts
More informationAeolus Pharmaceuticals Announces First Quarter Fiscal Year 2012 Financial Results
February 13, 2012 Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2012 Financial Results MISSION VIEJO, CA -- (MARKET WIRE) -- 02/13/12 -- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS:
More informationDigital River, Inc. Fourth Quarter Results (In thousands, except share data) Subject to reclassification
(In thousands, except share data) Consolidated Balance Sheets (Unaudited) 2012 2011 Assets Current assets Cash and cash equivalents $ 542,851 $ 497,193 Short-term investments 162,794 223,349 Accounts receivable,
More informationADVANSOURCE BIOMATERIALS ANNOUNCES THIRD QUARTER RESULTS FOR FISCAL 2010
ADVANSOURCE BIOMATERIALS ANNOUNCES THIRD QUARTER RESULTS FOR FISCAL 2010 Wilmington, MA. February 17, 2010 AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) Revenues: Subscription $ 179,907 $ 117,375 Professional services and other 32,057 21,715 Total revenues 211,964
More informationRevenues $ 130,168 $ 120,563 $ 66,237 $ 67,898 Cost of revenues 93,258 92,984 46,668 52,717. Gross profit 36,910 27,579 19,569 15,181
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (except share and per share data) June 30, June 30, 2017 2016 2017 2016 Revenues $ 130,168 $ 120,563 $ 66,237 $ 67,898 Cost of revenues 93,258 92,984 46,668
More informationPLURISTEM THERAPEUTICS INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 o TRANSITION REPORT UNDER
More informationADMA Biologics Reports Full Year 2017 Financial Results
March 5, 2018 ADMA Biologics Reports Full Year 2017 Financial Results RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ( ADMA or the Company ), a
More information1 sur 9 26/07/ :19
1 sur 9 26/07/2012 13:19 Print Page Close Window Press Releases Celgene Reports Second Quarter 2012 Operating and Financial Results Total Revenue of $1.37 Billion and Net Product Sales of $1.34 Billion,
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) September 30, 2016 September 30, 2015 September 30, 2016 September 30, 2015 Revenues: Subscription $ 318,934
More informationGALENA BIOPHARMA, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event
More information19925 Stevens Creek Blvd., Suite 100 Cupertino, CA 95014
Dear Stockholders: 19925 Stevens Creek Blvd., Suite 100 Cupertino, CA 95014 You are invited to attend the Annual Meeting of Stockholders (the Annual Meeting ) of Cellular Biomedicine Group, Inc. (the Company
More informationAPT SYSTEMS, INC. FINANCIAL STATEMENTS
FINANCIAL STATEMENTS APT SYSTEMS, INC. FINANCIAL STATEMENTS (AUDITED) For the Periods Ended January 31, 2016 and 2015 APT SYSTEMS, INC. Balance Sheets As of January 31, 2016 and 2015 ASSETS Current Assets
More informationChina Pharma Holdings, Inc. Reports Full Year 2016 Financial Results
China Pharma Holdings, Inc. Reports Full Year 2016 Financial Results HAIKOU CITY, China, March 31, 2017 - China Pharma Holdings, Inc. (NYSE MKT: CPHI) ( China Pharma, the Company or We ), an NYSE MKT listed
More informationEL PASO NATURAL GAS COMPANY, L.L.C. CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2013 and 2012 Unaudited
CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2013 and Unaudited TABLE OF CONTENTS Page Number Consolidated Financial Statements Consolidated Statements of Income and Comprehensive
More informationStatement of Earnings
audited financial statements Statement of Earnings General Electric Company and consolidated affiliates For the years ended December 31 (In millions; per-share amounts in dollars) 2009 2008 2007 Revenues
More informationBio-Techne Releases Fourth Quarter Fiscal 2015 Results
August 6, 2015 Bio-Techne Releases Fourth Quarter Fiscal 2015 Results MINNEAPOLIS, Aug. 6, 2015 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) December 31, 2017 December 31, 2016 December 31, 2017 December 31, 2016 Revenues: Subscription $ 497,232
More informationABB Ltd Interim Consolidated Income Statements (unaudited)
ABB Ltd Interim Consolidated Income Statements (unaudited) ($ in millions, except per share data in $) Mar. 31, 2013 Mar. 31, 2012 Sales of products 8'191 7'423 Sales of services 1'524 1'484 Total revenues
More informationRenren Announces Unaudited Fourth Quarter and Fiscal Year 2017 Financial Results
Renren Announces Unaudited Fourth Quarter and Fiscal Year 2017 Financial Results BEIJING, China, May 7, 2018 Renren Inc. (NYSE: RENN) ("Renren" or the "Company"), which operates a social networking service
More informationU.S. STEM CELL, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended
More informationCelgene Reports First Quarter 2009 Operating and Financial Results. SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 30, Celgene Corporation (NASDAQ: CELG):
Celgene Reports First Quarter 2009 Operating and Financial Results SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 30, 2009-- Celgene Corporation (NASDAQ: CELG): REVLIMID Continues Gains in Multiple Myeloma Both in
More informationFinancial Statements. Annual Audited. For the years ended April 30, 2012 and 2011
Financial Statements Annual Audited CRITICAL OUTCOME TECHNOLOGIES INC. Page 2 Financial Statements Table of Contents Page Financial Statements Independent Auditors' Report 3 Statements of Financial Position
More informationMoleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2017
August 14, 2017 Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2017 HOUSTON, TX -- (Marketwired) -- 08/14/17 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin"
More informationImmunotherapy approaches to breast cancer management
Immunotherapy approaches to breast cancer management Corporate Office - US 820 Heinz Avenue Berkeley, CA, 94710 Tel: 1-888-485-6340 Fax: 424-245-3719 Corporate Office - Canada Suite 300 - Bellevue Centre
More informationicad REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS
icad REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS PowerLook Tomo Detection Version 2.0 Submitted for FDA Approval Conference call today at 4:30 p.m. ET NASHUA, N.H. (August 14, 2018) icad, Inc. (NASDAQ:
More informationNektar Therapeutics Reports Financial Results for the First Quarter of 2013
May 9, 2013 Nektar Therapeutics Reports Financial Results for the First Quarter of 2013 SAN FRANCISCO, May 9, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results
More informationConsolidated Balance Sheets
Consolidated Balance Sheets March 31 2015 2016 2016 Assets: Current assets Cash and cash equivalents 726,888 600,897 $ 5,317,673 Marketable securities 19,033 28,012 247,894 Notes and accounts receivable:
More informationAtossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update
May 5, 2016 Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update Conference Call to Be Held Today at 4:30 pm Eastern Time SEATTLE, WA -- (Marketwired) -- 05/05/16
More informationResMed Inc. (Exact Name of Registrant as Specified in Charter)
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January
More informationResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2018
NEWS RELEASE ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2018 1/22/2018 Revenue increased 13% to $601.3 million; up 11% on a constant currency basis GAAP-diluted earnings per share
More informationJABIL CIRCUIT, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) 2011 2010 ASSETS Current assets: Cash and cash equivalents $ 888,611 $ 744,329 Trade accounts receivable, net 1,100,926 1,408,319 Inventories 2,227,339
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited)
ServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Revenues: Three Months Ended March 31, 2018 March 31, 2017 *As Adjusted Subscription
More informationBAXALTA INCORPORATED (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended
More informationAtossa Genetics Announces Second Quarter 2016 Financial Results and Provides Company Update
August 12, 2016 Atossa Genetics Announces Second Quarter 2016 Financial Results and Provides Company Update Conference Call to Be Held Monday, August 15, 2016 at 4:30 pm Eastern Time SEATTLE, WA -- (Marketwired)
More informationConcord Medical Announces Fourth Quarter and Fiscal Year 2010 Financial Results Full Year Revenues up 33%, Company Opens 33 New Centers in 2010
Concord Medical Announces Fourth Quarter and Fiscal Year 2010 Financial Results Full Year Revenues up 33%, Company Opens 33 New Centers in 2010 BEIJING, March 28, 2011 /PRNewswire-Asia-FirstCall/ -- Concord
More informationicad REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS AND ANNOUNCES $13 MILLION CREDIT FACILITY WITH SILICON VALLEY BANK
icad REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS AND ANNOUNCES $13 MILLION CREDIT FACILITY WITH SILICON VALLEY BANK Conference Call today at 4:30 p.m. ET NASHUA, N.H. (August 8, 2017) icad, Inc. (Nasdaq:
More informationInterest expense 6,109 5,771 Interest income (617) (1,611) Foreign exchange (gain) / loss (27) 1,272 Net finance costs 5,465 5,432
Condensed interim consolidated statement of income For the three months ended September 30 Unaudited Unaudited* Continuing operations Revenue 205,406 370,982 Cost of sales 165,457 288,177 Gross profit
More informationNeuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results
May 15, 2018 Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results GERMANTOWN, Md., May 15, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C FORM 10-Q. For the quarterly period ended December 31, 2010
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q þ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended
More informationAGILENT TECHNOLOGIES, INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) (Unaudited)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) Twelve Months Ended October 31, Percent 2002 2001 Inc/(Dec) Orders $ 6,013 $ 6,414 (6%) Net revenue $ 6,010 $ 8,396
More informationicad REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS
icad REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS Fourth quarter total revenues increased 14% year-over-year; total revenues increased 22% excluding MRI asset sale Conference call today
More informationDOUBLE-DIGIT SALES GROWTH DRIVES STRONG FOURTH QUARTER RESULTS FOR EDWARDS LIFESCIENCES
Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amanda C. Fowler, 949-250-5070 Investor
More informationAs of December 31, As of. Assets Current assets:
CONSOLIDATED BALANCE SHEETS (In millions, except share and par value amounts which are reflected in thousands, and par value per share amounts) Assets Current assets: As of December 31, 2011 As of December
More informationAbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results
PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results Reports Full-Year Diluted EPS of $3.63 on a GAAP Basis; Adjusted Diluted EPS of $4.82, Reflecting Growth of 12.4 Percent
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited)
ServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Revenues: Subscription $ 626,567 $ 449,506 $ 1,755,174 $ 1,239,762 Professional
More informationPressure BioSciences, Inc. Reports First Quarter 2016 Financial Results and Provides Business Update
May 18, 2016 Pressure BioSciences, Inc. Reports First Quarter 2016 Financial Results and Provides Business Update Quarterly Products and Services Revenue Increases 26% Year/Year; Sales of Instruments and
More informationO: O:
For investors For media Amy Wakeham Jayme Rubenstein O: 858-836-5000 O: 858-836-6798 investorrelations@resmed.com news@resmed.com ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2019
More informationWest Pharmaceutical Services, Inc. RBC Capital Markets Global Healthcare Conference
West Pharmaceutical Services, Inc. Eric M. Green, President & CEO William J. Federici, Senior Vice President & CFO February 21, 2018 Safe Harbor Statement Cautionary Statement Under the Private Securities
More information$ 431,923 $ 208,042 $ 223, % $ 637,022 $ 345,704 $ 291, % 68 % 68 % - % 67 % 66 % 1 %
Three Months Ended June 30, Period-to-Period Change Six Months Ended June 30, Period-to-Period Change 2018 2017 $ % 2018 2017 $ % Revenue $ 632,369 $ 306,683 $ 325,686 106 % $ 945,548 $ 522,914 $ 422,634
More informationMyriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results
May 8, 2018 Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results Total Revenues of $193.5 Million GAAP Diluted EPS of $0.16 and Adjusted EPS of $0.31 Up 15 Percent Company Raises Both Revenue
More informationGoogle Inc. CONSOLIDATED BALANCE SHEETS
Google Inc. CONSOLIDATED BALANCE SHEETS (In millions, except share and par value amounts which are reflected in thousands,and par value per share amounts) As of December 31, 2013 As of March 31, 2014 Assets
More informationCryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma
Cryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma - - - Biopharma revenue up 69% year-over-year; 33 new clinical trials supported during second quarter IRVINE, CA Aug 8, 2017
More informationFinancial Statement Balance Sheet
Financial Statement Balance Sheet Page 1 of 1 Financial Statement Balance Sheet Accounting Title 2014/09/30 2013/12/31 2013/09/30 Balance Sheet Assets Current assets Cash and cash equivalents Total cash
More informationKLA-Tencor Reports Fiscal 2016 First Quarter Results And Agreement To Combine With Lam Research
October 21, 2015 KLA-Tencor Reports Fiscal 2016 First Quarter Results And Agreement To Combine With Lam Research MILPITAS, Calif., Oct. 21, 2015 /PRNewswire/ -- (NASDAQ: KLAC) today announced operating
More informationNOVOHEART HOLDINGS INC. Suite West Pender Street Vancouver British Columbia V6C 2V6 Canada
October 25, 2017 NOVOHEART HOLDINGS INC. Suite 1430 800 West Pender Street Vancouver British Columbia V6C 2V6 Canada Novoheart Holdings Inc. Reports Fourth Quarter and Fiscal 2017 Financial Results Vancouver,
More informationAGILENT TECHNOLOGIES, INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) (Unaudited)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) Three Months Ended January 31, Percent 2003 2002 Inc/(Dec) Orders $ 1,358 $ 1,465 (7%) Net revenue $ 1,412 $ 1,426
More informationLEXMARK INTERNATIONAL GROUP, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (In Millions, Except Per Share Amounts) (Unaudited)
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (In Millions, Except Per Share Amounts) Revenues Cost of revenues Gross profit Three Months Ended $787.0 501.8 285.20 $672.1 425.5 246.60 Percent Change 17%
More informationASC605 to ASC606 Transition
ASC605 to ASC606 Transition Summary Workday Adoption Background Workday has elected early adoption of ASC606 (as of 2/1/2017) Full retrospective adoption method (FY16 & FY17 restated) FY17 has also been
More informationFourth Quarter and Full-Year 2018 Earnings Call February 20, 2019
Fourth Quarter and Full-Year 2018 Earnings Call February 20, 2019 1 2019 2017 ServiceSource International, Inc. All rights reserved. Important Information This presentation refers to certain non-gaap financial
More informationIllumina Reports Financial Results for Third Quarter of Fiscal Year 2017
Investors: Jacquie Ross, CFA 858-882-2172 ir@illumina.com Media: Eric Endicott 858-882-6822 pr@illumina.com Illumina Reports Financial Results for Third Quarter of Fiscal Year San Diego -- (BUSINESS WIRE)
More information